FDA OKs First-Line Immunotherapy in Liver Cancer

]]>(MedPage Today) -- The FDA on Friday approved the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq) for the first-line treatment of unresectable or metastatic liver cancer, in combination with bevacizumab (Avastin), an inhibitor of the...